KAIST Unveils Breakthrough Technology to Reverse Cancer Cells to Normal

The Korea Advanced Institute of Science and Technology (KAIST) has announced a groundbreaking approach to cancer treatment, unveiling a method to revert cancer cells to a state resembling normal cells.

Led by Professor Kwang-Hyun Cho, this innovative research shifts the focus from destroying cancer cells to reprogramming them at the genetic level. This breakthrough could lead to more affordable treatments, fewer side effects, and the development of personalized medical solutions.

KAIST, a public research university based in Daejeon, South Korea, was established in 1971 as the nation’s first institution dedicated to science and engineering.

The new KAIST research utilized advanced digital twin models to study gene behavior during normal cell development. Through this analysis, the team identified three pivotal genes—HDAC2, FOXA2, and MYB—capable of inducing colon cancer cells to behave like normal cells.

Laboratory and animal tests demonstrated that this method could significantly slow or halt tumor growth. The discovery opens doors to innovative products, including gene-editing tools, cancer detection tests, and personalized treatment solutions. Such advancements address critical needs for effective, affordable, and less invasive cancer therapies.

“The fact that cancer cells can be converted back to normal cells is an astonishing phenomenon,” said Professor Cho. “This study proves that such reversion can be systematically induced. By introducing the concept of reversible cancer therapy, we provide a foundational technology for identifying future therapeutic targets.”

BioRevert, a KAIST spin-off, has secured the rights to commercialize this revolutionary technology. The company plans to develop gene-editing treatments and cell-based reprogramming kits for clinical use. Its focus on precision oncology aims to enhance patient outcomes while addressing inefficiencies in traditional cancer care.

The KAIST innovation comes as the precision medicine market, valued at $66 billion in 2023, is poised for double-digit CAGR growth over the next decade. By bridging gaps in existing therapies, KAIST’s breakthrough aligns with biotech and healthcare investment trends, particularly those emphasizing digital tools and AI integration.

KAIST’s technology addresses persistent challenges in oncology, including resistance to conventional treatments and severe side effects. As BioRevert advances towards commercialization, the healthcare and investment sectors are closely monitoring its progress. With potential applications in genetic editing, diagnostics, and targeted therapy, this innovation could redefine cancer care.

For venture capital and private equity investors, BioRevert represents a compelling opportunity. Its strategic focus on licensing and product development promises access to high-margin revenue streams in underserved oncology markets. Additionally, its use of digital twin simulations to inform genetic therapy positions the company for applications extending beyond cancer treatment.